ClinicalTrials.gg
CompletedNCT02581345Updated Oct 17, 2018Results posted

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

A Phase 3 interventional study of M923 and Humira in Chronic Plaque Psoriasis and Psoriasis, sponsored by Momenta Pharmaceuticals, Inc.. Completed at 90 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by Momenta Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
572
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
3rd of 48
572 · median 148
Started
2015
with 2 others
Phase 3
26 of 48
1 open now
Registered
32nd of 48
by date

Among the 48 studies testing adalimumab in Psoriasis, this one is the 3rd largest by enrollment, is one of 3 that started in 2015, is one of 26 in phase 3, and was the 32nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.

03

Conditions studied

  • Chronic Plaque Psoriasis
  • Psoriasis

Browse trials for

Keywords

  • Moderate to severe chronic plaque psoriasis
  • Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be able to understand and communicate with the investigator and comply with the requirements of the study
  2. Chronic plaque-type psoriasis diagnosed for at least 6 months before screening
  3. Stable plaque psoriasis
  4. History of receipt of or candidate for therapy.
  5. Moderate to severe psoriasis at screening and baseline
  6. Must be willing and able to self-administer SC injections or have a caregiver available to administer injections
  7. Male participants of must employ a highly effective measure
  8. Female participants must have a negative pregnancy test; are not planning to become pregnant; and must not be lactating. Female participants must also agree to employ a highly effective contraceptive measure.

Exclusion criteria

Exclusion Criteria:

  1. Forms of psoriasis other than chronic plaque-type
  2. Drug-induced psoriasis.
  3. Other skin conditions which would interfere with assessment of psoriasis
  4. Medical conditions other than psoriasis for which systemic were used in the last year prior to screening
  5. Other inflammatory conditions other than psoriasis or psoriatic arthritis
  6. Prior use of systemic tumor necrosis factor (TNF) inhibitors, or 2 or more non-TNF biologic therapies
  7. Ongoing use of prohibited psoriasis treatments
  8. Ongoing use of other non-psoriasis prohibited treatments
  9. All other prior non-psoriasis concomitant treatments must be on a stable dose for at least 4 weeks
  10. Laboratory abnormalities at screening deemed by the investigator
  11. Any condition or illness which in the opinion of the investigator or sponsor poses an unacceptable safety risk
  12. History of latex allergy
  13. History of or current signs or symptoms or diagnosis of a demyelinating disorder
  14. History of or current Class III or IV congestive heart failure
  15. Signs, symptoms, or diagnosis of lymphoproliferative disorders, lymphoma, leukemia, myeloproliferative disorders, or multiple myeloma
  16. Current or history of any malignancy except adequately treated or excised non basal cell or squamous cell cancer of the skin or cervical carcinoma in situ; no more than 3 lifetime basal cell and squamous cell carcinomas permitted
  17. Chronic infections, recurrent infections; recent infection to be evaluated
  18. History of or presence of (HIV), or (HBV) or C virus ()
  19. History of active tuberculosis (TB) or untreated or inadequately treated latent TB.
  20. Exposure to an product ≤30 days prior to enrollment or participation in another clinical study during the course of this study
  21. Participant is a family member or employee of the investigator or site staff or study team
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
572 participants (actual)

Study arms

  • Experimental
    M923

    Participants assigned to receive M923

    Biological: M923

  • Active comparator
    Humira

    Participants assigned to receive Humira

    Biological: Humira

  • Other
    M923 and Humira

    Participants assigned to receive M923 and Humira

    Biological: M923 · Biological: Humira

Interventions

  • BiologicalM923

    Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)

    Also known as: Adalimumab

  • BiologicalHumira

    Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)

    Also known as: Adalimumab

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 16

    The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 75 are defined as having an improvement (reduction) of at least 75% in the Week 16 PASI score compared to the score at Baseline.

    Time frame: Baseline; Week 16

Secondary outcomes

  1. Percentage of Participants With a Response of Clear or Almost Clear on the Static Physician Global Assessment (sPGA) at Week 16

    The sPGA response rate was defined as the percentage of participants who had achieved a clear or almost clear response on the 6-point sPGA scale. The sPGA was the physician's determination of the participant's psoriasis lesions overall at a given time point. Overall lesions were categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis was assessed at a given time point on a 6-point scale on which 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe.

    Time frame: Week 16

  2. Number of Participants Achieving PASI 50 Response at Week 16

    The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 50 are defined as having an improvement (reduction) of at least 50% compared to Baseline.

    Time frame: Baseline; Week 16

  3. Number of Participants Achieving PASI 50 Response at Week 52 (Follow-Up Visit)

    The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 50 are defined as having an improvement (reduction) of at least 50% compared to Baseline.

    Time frame: Baseline; Week 52

  4. Number of Participants Achieving PASI 75 Response at Week 52 (Follow-Up Visit)

    The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 75 are defined as having an improvement (reduction) of at least 75% compared to Baseline.

    Time frame: Baseline; Week 52

  5. Number of Participants Achieving PASI 90 Response at Week 16

    The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 90 are defined as having an improvement (reduction) of at least 90% compared to Baseline.

    Time frame: Baseline; Week 16

  6. Number of Participants Achieving PASI 90 Response at Week 52 (Follow-Up Visit)

    The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 90 are defined as having an improvement (reduction) of at least 90% compared to Baseline.

    Time frame: Baseline; Week 52

  7. Absolute PASI Score at Baseline

    The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.

    Time frame: Baseline

  8. Absolute PASI Score at Week 16

    The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.

    Time frame: Week 16

  9. Absolute PASI Score at Week 52 (Follow-Up Visit)

    The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.

    Time frame: Week 52

  10. Percent Change From Baseline in PASI Score at Week 16

    The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Percent change from Baseline was calculated as: (post-Baseline value - Baseline value) / (Baseline value) \* 100.

    Time frame: Baseline; Week 16

  11. Percent Change From Baseline in PASI Score at Week 52 (Follow-Up Visit)

    The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Percent change from Baseline was calculated as: (post-Baseline value - Baseline value) / (Baseline value) \* 100.

    Time frame: Baseline; Week 52

  12. Health-Related Quality of Life During Treatment: Dermatology Life Quality Index (DLQI) Score at Baseline

    The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.

    Time frame: Baseline

  13. Health-Related Quality of Life During Treatment: DLQI Score at Week 16

    The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.

    Time frame: Week 16

  14. Health-Related Quality of Life During Treatment: DLQI Score at Week 48 (Completion/Termination Visit)

    The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.

    Time frame: Week 48

  15. Health-Related Quality of Life During Treatment: EuroQoL 5-Dimension Health Status Questionnaire (EQ-5D-5L) at Baseline

    The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine". Baseline was defined as the last scheduled observation prior to dosing, typically Day 1, predose.

    Time frame: Baseline

  16. Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 16

    The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine".

    Time frame: Week 16

  17. Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 48 (Completion/Termination Visit)

    The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine".

    Time frame: Week 48

  18. Number of Participants With Clinically Meaningful Changes in Vital Signs

    Vital signs included body temperature, respiratory rate, pulse rate, systolic and diastolic blood pressure, and weight. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.

    Time frame: Up to Week 52

  19. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Baseline

    Laboratory results included hematology \[Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Gamma glutamyl transferase, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Potassium, Urea, Creatinine, Phosphate, Glucose, and Uric acid) and urinalysis \[Specific Gravity\] parameters. Laboratory results of a few hematology (Red Blood Cell Count and Monocytes absolute), chemistry (Alkaline Phosphatase, Total bilirubin, Sodium, Chloride, and Albumin), and urinalysis (pH) parameters were not assessed at Baseline and Week 16. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.

    Time frame: Baseline

  20. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 16

    Laboratory results included hematology \[Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Gamma glutamyl transferase, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Potassium, Urea, Creatinine, Phosphate, Glucose, and Uric acid) and urinalysis \[Specific Gravity\] parameters. Laboratory results of a few hematology (Red Blood Cell Count and Monocytes absolute), chemistry (Alkaline Phosphatase, Total bilirubin, Sodium, Chloride, and Albumin), and urinalysis (pH) parameters were not assessed at Baseline and Week 16. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.

    Time frame: Week 16

  21. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 48 (Completion/Termination Visit)

    Laboratory results included hematology \[Red Blood Cell Count, Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes absolute, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Alkaline Phosphatase, Gamma glutamyl transferase, Total bilirubin, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Sodium, Potassium, Chloride, Urea, Creatinine, Albumin, Phosphate, Glucose, and Uric acid) and urinalysis \[pH and Specific Gravity\] parameters. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.

    Time frame: Week 48

  22. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Baseline

    Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.

    Time frame: Baseline

  23. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 16

    Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.

    Time frame: Week 16

  24. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 48 (Completion/Termination Visit)

    Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.

    Time frame: Week 48

  25. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs are adverse events that occurred during or after study drug administration. For more details on adverse events please refer the safety section.

    Time frame: Up to Week 52

  26. Pharmacokinetics: Serum Concentrations by Treatment

    Serum samples were collected at Baseline (Week 0, perdose), approximately 1 week (peak) after IP administration (Weeks 8 and 16), and 2 weeks after dose administration as a trough sample collected prior to the next dose administration (Weeks 17, 21, 25, 29, 37, 41).

    Time frame: Baseline (Week 0), Week 8, 16, 17, 21, 25, 29, 37, and 41

  27. Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA) at Baseline

    The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.

    Time frame: Baseline (Week 0)

  28. Immunogenicity: Number of Participants With ADA at Week 16

    The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.

    Time frame: Week 16

  29. Immunogenicity: Number of Participants With ADA at Week 25

    The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.

    Time frame: Week 25

  30. Immunogenicity: Number of Participants With ADA at Week 52 (Completion/Termination Visit)

    The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.

    Time frame: Week 52

  31. Immunogenicity: Number of Participants With ADA and nADA by Titer at Baseline

    The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.

    Time frame: Baseline (Week 0)

  32. Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 16

    The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.

    Time frame: Week 16

  33. Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 25

    The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.

    Time frame: Week 25

  34. Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 52 (Completion/Termination Visit)

    The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.

    Time frame: Week 52

  35. Median Time to Seroconversion

    Time to seroconversion (in days) was defined as the time to the observation of the first confirmed positive ADA response. Participants with confirmed positive ADA response at baseline (Week 0 predose) were excluded.

    Time frame: Up to Week 52

07

Results

Posted Sep 12, 2018

Participant flow

A total of 572 participants were enrolled and randomized equally into M923 and European Union reference protein product (EU RPP) arms. One participant in each arm did not receive any treatment. The 263 participants completing EU RPP treatment in Part 1 were randomized to 1 of 2 treatment arms in Part 2 (Transition and Continuous).

Part 1: up to Week 16
Participant flow — Part 1: up to Week 16
MilestonePart 1 and Part 2: M923Part 1: EU RPPPart 1: EU RPP; Part 2: TransitionPart 1: EU RPP; Part 2: Continous
Started28628600
Completed27126300
Not completed152300
Withdrew: Adverse event3800
Withdrew: Physician decision2400
Withdrew: Withdrawal by subject4700
Withdrew: Lost to follow-up2000
Withdrew: Unspecified reason3300
Withdrew: Did not receive treatment1100
Part 2: Week 17 to Week 47
Participant flow — Part 2: Week 17 to Week 47
MilestonePart 1 and Part 2: M923Part 1: EU RPPPart 1: EU RPP; Part 2: TransitionPart 1: EU RPP; Part 2: Continous
Started2710132131
Completed2420117119
Not completed2901512
Withdrew: Adverse event5022
Withdrew: Physician decision3021
Withdrew: Withdrawal by subject9075
Withdrew: Failure to achieve at least a pasi 508032
Withdrew: Lost to follow-up2001
Withdrew: Unspecified reason2011

Outcome measures

PrimaryPercentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 16

The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 75 are defined as having an improvement (reduction) of at least 75% in the Week 16 PASI score compared to the score at Baseline.

Time frame:
Baseline; Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 16
percentage of participantsPart 1: M923Part 1: EU RPP
Percentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 1680.1 (74.9 to 84.8)79.0 (73.6 to 83.7)
Statistical analysis
  • Part 1: M923 vs Part 1: EU RPP · Difference in proportion (m923 - eu rpp): 0.014 · 90% CI -0.043 to 0.072
  • Part 1: M923 vs Part 1: EU RPP · Difference in proportion (m923 - eu rpp): 0.014 · 95% CI -0.054 to 0.082
SecondaryPercentage of Participants With a Response of Clear or Almost Clear on the Static Physician Global Assessment (sPGA) at Week 16

The sPGA response rate was defined as the percentage of participants who had achieved a clear or almost clear response on the 6-point sPGA scale. The sPGA was the physician's determination of the participant's psoriasis lesions overall at a given time point. Overall lesions were categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis was assessed at a given time point on a 6-point scale on which 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Response of Clear or Almost Clear on the Static Physician Global Assessment (sPGA) at Week 16
percentage of participantsPart 1: M923Part 1: EU RPP
Percentage of Participants With a Response of Clear or Almost Clear on the Static Physician Global Assessment (sPGA) at Week 1668.9 (63.0 to 74.4)66.1 (60.1 to 71.7)
Statistical analysis
  • Part 1: M923 vs Part 1: EU RPP · Difference in proportion (m923 - eu rpp): 0.031 · 95% CI -0.048 to 0.110
SecondaryNumber of Participants Achieving PASI 50 Response at Week 16

The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 50 are defined as having an improvement (reduction) of at least 50% compared to Baseline.

Time frame:
Baseline; Week 16
Reported as:
Count of participants · Participants
Number of Participants Achieving PASI 50 Response at Week 16
ParticipantsPart 1: M923Part 1: EU RPP
Number of Participants Achieving PASI 50 Response at Week 16243253
Statistical analysis
  • Part 1: M923 vs Part 1: EU RPP · Difference in proportion (m923 - eu rpp): -0.022 · 90% CI -0.061 to 0.016
  • Part 1: M923 vs Part 1: EU RPP · Difference in proportion (m923 - eu rpp): -0.022 · 95% CI -0.069 to 0.024
SecondaryNumber of Participants Achieving PASI 50 Response at Week 52 (Follow-Up Visit)

The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 50 are defined as having an improvement (reduction) of at least 50% compared to Baseline.

Time frame:
Baseline; Week 52
Reported as:
Count of participants · Participants
Number of Participants Achieving PASI 50 Response at Week 52 (Follow-Up Visit)
ParticipantsPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Number of Participants Achieving PASI 50 Response at Week 52 (Follow-Up Visit)228111113
SecondaryNumber of Participants Achieving PASI 75 Response at Week 52 (Follow-Up Visit)

The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 75 are defined as having an improvement (reduction) of at least 75% compared to Baseline.

Time frame:
Baseline; Week 52
Reported as:
Count of participants · Participants
Number of Participants Achieving PASI 75 Response at Week 52 (Follow-Up Visit)
ParticipantsPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Number of Participants Achieving PASI 75 Response at Week 52 (Follow-Up Visit)20296101
SecondaryNumber of Participants Achieving PASI 90 Response at Week 16

The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 90 are defined as having an improvement (reduction) of at least 90% compared to Baseline.

Time frame:
Baseline; Week 16
Reported as:
Count of participants · Participants
Number of Participants Achieving PASI 90 Response at Week 16
ParticipantsPart 1: M923Part 1: EU RPP
Number of Participants Achieving PASI 90 Response at Week 16165147
Statistical analysis
  • Part 1: M923 vs Part 1: EU RPP · Difference in proportion (m923 - eu rpp): 0.080 · 90% CI 0.010 to 0.149
  • Part 1: M923 vs Part 1: EU RPP · Difference in proportion (m923 - eu rpp): 0.080 · 95% CI -0.004 to 0.162
SecondaryNumber of Participants Achieving PASI 90 Response at Week 52 (Follow-Up Visit)

The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 90 are defined as having an improvement (reduction) of at least 90% compared to Baseline.

Time frame:
Baseline; Week 52
Reported as:
Count of participants · Participants
Number of Participants Achieving PASI 90 Response at Week 52 (Follow-Up Visit)
ParticipantsPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Number of Participants Achieving PASI 90 Response at Week 52 (Follow-Up Visit)1597177
SecondaryAbsolute PASI Score at Baseline

The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.

Time frame:
Baseline
Reported as:
Mean · units on a scale
Absolute PASI Score at Baseline
units on a scalePart 1: M923Part 1: EU RPP
Absolute PASI Score at Baseline21.34 ± 9.26820.29 ± 8.266
SecondaryAbsolute PASI Score at Week 16

The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.

Time frame:
Week 16
Reported as:
Mean · units on a scale
Absolute PASI Score at Week 16
units on a scalePart 1: M923Part 1: EU RPP
Absolute PASI Score at Week 162.58 ± 4.0922.50 ± 3.098
SecondaryAbsolute PASI Score at Week 52 (Follow-Up Visit)

The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.

Time frame:
Week 52
Reported as:
Mean · units on a scale
Absolute PASI Score at Week 52 (Follow-Up Visit)
units on a scalePart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Absolute PASI Score at Week 52 (Follow-Up Visit)2.76 ± 4.7682.85 ± 4.9132.67 ± 3.919
SecondaryPercent Change From Baseline in PASI Score at Week 16

The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Percent change from Baseline was calculated as: (post-Baseline value - Baseline value) / (Baseline value) \* 100.

Time frame:
Baseline; Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in PASI Score at Week 16
percent changePart 1: M923Part 1: EU RPP
Percent Change From Baseline in PASI Score at Week 16-86.21 ± 20.065-86.79 ± 15.756
SecondaryPercent Change From Baseline in PASI Score at Week 52 (Follow-Up Visit)

The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Percent change from Baseline was calculated as: (post-Baseline value - Baseline value) / (Baseline value) \* 100.

Time frame:
Baseline; Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in PASI Score at Week 52 (Follow-Up Visit)
percent changePart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Percent Change From Baseline in PASI Score at Week 52 (Follow-Up Visit)-86.43 ± 22.570-85.53 ± 21.771-85.64 ± 20.968
SecondaryHealth-Related Quality of Life During Treatment: Dermatology Life Quality Index (DLQI) Score at Baseline

The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.

Time frame:
Baseline
Reported as:
Mean · units on a scale
Health-Related Quality of Life During Treatment: Dermatology Life Quality Index (DLQI) Score at Baseline
units on a scalePart 1: M923Part 1: EU RPP
Health-Related Quality of Life During Treatment: Dermatology Life Quality Index (DLQI) Score at Baseline12.5 ± 7.1310.5 ± 6.71
SecondaryHealth-Related Quality of Life During Treatment: DLQI Score at Week 16

The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.

Time frame:
Week 16
Reported as:
Mean · units on a scale
Health-Related Quality of Life During Treatment: DLQI Score at Week 16
units on a scalePart 1: M923Part 1: EU RPP
Health-Related Quality of Life During Treatment: DLQI Score at Week 162.4 ± 4.042.1 ± 3.50
SecondaryHealth-Related Quality of Life During Treatment: DLQI Score at Week 48 (Completion/Termination Visit)

The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.

Time frame:
Week 48
Reported as:
Mean · units on a scale
Health-Related Quality of Life During Treatment: DLQI Score at Week 48 (Completion/Termination Visit)
units on a scalePart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Health-Related Quality of Life During Treatment: DLQI Score at Week 48 (Completion/Termination Visit)2.1 ± 3.771.6 ± 2.832.1 ± 3.97
SecondaryHealth-Related Quality of Life During Treatment: EuroQoL 5-Dimension Health Status Questionnaire (EQ-5D-5L) at Baseline

The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine". Baseline was defined as the last scheduled observation prior to dosing, typically Day 1, predose.

Time frame:
Baseline
Reported as:
Mean · units on a scale
Health-Related Quality of Life During Treatment: EuroQoL 5-Dimension Health Status Questionnaire (EQ-5D-5L) at Baseline
units on a scalePart 1: M923Part 1: EU RPP
Health-Related Quality of Life During Treatment: EuroQoL 5-Dimension Health Status Questionnaire (EQ-5D-5L) at Baseline71.3 ± 18.7072.5 ± 20.27
SecondaryHealth-Related Quality of Life During Treatment: EQ-5D-5L at Week 16

The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine".

Time frame:
Week 16
Reported as:
Mean · units on a scale
Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 16
units on a scalePart 1: M923Part 1: EU RPP
Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 1683.7 ± 12.3883.4 ± 13.92
SecondaryHealth-Related Quality of Life During Treatment: EQ-5D-5L at Week 48 (Completion/Termination Visit)

The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine".

Time frame:
Week 48
Reported as:
Mean · units on a scale
Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 48 (Completion/Termination Visit)
units on a scalePart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 48 (Completion/Termination Visit)85.3 ± 13.8383.9 ± 14.9284.2 ± 12.98
SecondaryNumber of Participants With Clinically Meaningful Changes in Vital Signs

Vital signs included body temperature, respiratory rate, pulse rate, systolic and diastolic blood pressure, and weight. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Changes in Vital Signs
ParticipantsPart 1: M923Part 1: EU RPPPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Number of Participants With Clinically Meaningful Changes in Vital Signs00000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Baseline

Laboratory results included hematology \[Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Gamma glutamyl transferase, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Potassium, Urea, Creatinine, Phosphate, Glucose, and Uric acid) and urinalysis \[Specific Gravity\] parameters. Laboratory results of a few hematology (Red Blood Cell Count and Monocytes absolute), chemistry (Alkaline Phosphatase, Total bilirubin, Sodium, Chloride, and Albumin), and urinalysis (pH) parameters were not assessed at Baseline and Week 16. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Baseline
ParticipantsPart 1: M923Part 1: EU RPP
Hemoglobin00
Hematocrit00
Platelet count00
Mean cell volume00
White blood cell count (total leucocytes)11
Neutrophils absolute21
Neutrophils10
Lymphocytes absolute11
Lymphocytes11
Monocytes00
Eosinophils absolute00
Eosinophils00
Aspartate transaminase00
Alanine transaminase11
Gamma glutamyl transferase14
Creatine kinase20
C-reactive protein62
Cholesterol24
Triglycerides32
Total protein01
Potassium10
Urea10
Creatinine00
Phosphate00
Glucose12
Uric acid20
Specific Gravity00
SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 16

Laboratory results included hematology \[Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Gamma glutamyl transferase, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Potassium, Urea, Creatinine, Phosphate, Glucose, and Uric acid) and urinalysis \[Specific Gravity\] parameters. Laboratory results of a few hematology (Red Blood Cell Count and Monocytes absolute), chemistry (Alkaline Phosphatase, Total bilirubin, Sodium, Chloride, and Albumin), and urinalysis (pH) parameters were not assessed at Baseline and Week 16. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 16
ParticipantsPart 1: M923Part 1: EU RPP
Hemoglobin11
Hematocrit11
Platelet count00
Mean cell volume01
White blood cell count (total leucocytes)20
Neutrophils absolute10
Neutrophils00
Lymphocytes absolute01
Lymphocytes01
Monocytes00
Eosinophils absolute10
Eosinophils10
Aspartate transaminase20
Alanine transaminase31
Gamma glutamyl transferase32
Creatine kinase20
C-reactive protein10
Cholesterol43
Triglycerides53
Total protein01
Potassium10
Urea00
Creatinine00
Phosphate00
Glucose23
Uric acid11
Specific Gravity00
SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 48 (Completion/Termination Visit)

Laboratory results included hematology \[Red Blood Cell Count, Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes absolute, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Alkaline Phosphatase, Gamma glutamyl transferase, Total bilirubin, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Sodium, Potassium, Chloride, Urea, Creatinine, Albumin, Phosphate, Glucose, and Uric acid) and urinalysis \[pH and Specific Gravity\] parameters. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 48 (Completion/Termination Visit)
ParticipantsPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Red Blood Cell Count101
Hemoglobin101
Hematocrit101
Platelet count100
Mean cell volume001
White blood cell count (total leucocytes)211
Neutrophils absolute312
Neutrophils300
Lymphocytes absolute001
Lymphocytes100
Monocytes absolute000
Monocytes100
Eosinophils absolute000
Eosinophils200
Aspartate transaminase201
Alanine transaminase503
Alkaline Phosphatase000
Gamma glutamyl transferase303
Total bilirubin101
Creatine kinase011
C-reactive protein300
Cholesterol732
Triglycerides1142
Total protein000
Sodium000
Potassium000
Chloride000
Urea000
Creatinine000
Albumin000
Phosphate000
Glucose530
Uric acid133
pH110
Specific Gravity000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Baseline

Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Baseline
ParticipantsPart 1: M923Part 1: EU RPP
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Baseline00
SecondaryNumber of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 16

Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 16
ParticipantsPart 1: M923Part 1: EU RPP
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 1620
SecondaryNumber of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 48 (Completion/Termination Visit)

Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 48 (Completion/Termination Visit)
ParticipantsPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 48 (Completion/Termination Visit)300
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs are adverse events that occurred during or after study drug administration. For more details on adverse events please refer the safety section.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPart 1: M923Part 1: EU RPPPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Number of Participants With Treatment-emergent Adverse Events (TEAEs)16919419999103
SecondaryPharmacokinetics: Serum Concentrations by Treatment

Serum samples were collected at Baseline (Week 0, perdose), approximately 1 week (peak) after IP administration (Weeks 8 and 16), and 2 weeks after dose administration as a trough sample collected prior to the next dose administration (Weeks 17, 21, 25, 29, 37, 41).

Time frame:
Baseline (Week 0), Week 8, 16, 17, 21, 25, 29, 37, and 41
Reported as:
Mean · nanograms per milliter (ng/mL)
Pharmacokinetics: Serum Concentrations by Treatment
nanograms per milliter (ng/mL)Part 1: M923Part 1: EU RPPPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Baseline (Week 0)/Predose302 ± 16.5301 ± 9.69———
Week 8/Peak9100 ± 54507640 ± 4370———
Week 16/Peak8580 ± 57006990 ± 5100———
Week 17/Trough——6900 ± 52705840 ± 48405340 ± 4050
Week 21/Trough——6630 ± 49606260 ± 49605100 ± 4040
Week 25/Trough——6790 ± 52106320 ± 52604970 ± 3870
Week 29/Trough——5990 ± 40205330 ± 40004840 ± 3480
Week 37/Trough——6120 ± 42205250 ± 41904830 ± 3680
Week 41/Trough——5950 ± 42305480 ± 41404740 ± 3710
SecondaryImmunogenicity: Number of Participants With Anti-Drug Antibodies (ADA) at Baseline

The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.

Time frame:
Baseline (Week 0)
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA) at Baseline
ParticipantsPart 1: M923Part 1: EU RPP
EU Humera1511
M92312
Overall Results1613
Neutralizing ADA42
SecondaryImmunogenicity: Number of Participants With ADA at Week 16

The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With ADA at Week 16
ParticipantsPart 1: M923Part 1: EU RPP
EU Humera135144
M92348
Overall Results139152
Neutralizing ADA2830
SecondaryImmunogenicity: Number of Participants With ADA at Week 25

The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.

Time frame:
Week 25
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With ADA at Week 25
ParticipantsPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
EU Humera1448092
M9231255
Overall result1568597
Neutralizing ADA552532
SecondaryImmunogenicity: Number of Participants With ADA at Week 52 (Completion/Termination Visit)

The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With ADA at Week 52 (Completion/Termination Visit)
ParticipantsPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
EU Humera1317380
M9231067
Overall result1417987
Neutralizing ADA402823
SecondaryImmunogenicity: Number of Participants With ADA and nADA by Titer at Baseline

The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.

Time frame:
Baseline (Week 0)
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With ADA and nADA by Titer at Baseline
ParticipantsPart 1: M923Part 1: EU RPP
No positive result266271
Predose positive result1613
SecondaryImmunogenicity: Number of Participants With ADA and nADA by Titer at Week 16

The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 16
ParticipantsPart 1: M923Part 1: EU RPP
Titers ≤ 1:16 (postdose positive ADAs)1626
Titers ≤ 1:16 (postdose positive nADAs)22
Titers > 1:16 to ≤ 1:128 (postdose positive ADAs)9073
Titers > 1:16 to ≤ 1:128 (postdose positive nADAs)176
Titers >1:128 to ≤ 1:152 (postdose positive ADAs)2740
Titers >1:128 to ≤ 1:152 (postdose positive nADAs)311
Titers >1:152 (postdose positive ADAs)613
Titers >1:152 (postdose positive nADAs)611
SecondaryImmunogenicity: Number of Participants With ADA and nADA by Titer at Week 25

The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.

Time frame:
Week 25
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 25
ParticipantsPart 1 and Part 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Titers ≤ 1:16 (postdose positive ADAs)241921
Titers ≤ 1:16 (postdose positive nADAs)624
Titers > 1:16 to ≤ 1:128 (postdose positive ADAs)863742
Titers > 1:16 to ≤ 1:128 (postdose positive nADAs)1747
Titers >1:128 to ≤ 1:152 (postdose positive ADAs)281422
Titers >1:128 to ≤ 1:152 (postdose positive nADAs)16610
Titers >1:152 (postdose positive ADAs)181512
Titers >1:152 (postdose positive nADAs)161311
SecondaryImmunogenicity: Number of Participants With ADA and nADA by Titer at Week 52 (Completion/Termination Visit)

The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 52 (Completion/Termination Visit)
ParticipantsPart 1 and Part 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Titers ≤ 1:16 (postdose positive ADAs)261117
Titers ≤ 1:16 (postdose positive nADAs)023
Titers > 1:16 to ≤ 1:128 (postdose positive ADAs)623738
Titers > 1:16 to ≤ 1:128 (postdose positive nADAs)1365
Titers >1:128 to ≤ 1:152 (postdose positive ADAs)231215
Titers >1:128 to ≤ 1:152 (postdose positive nADAs)962
Titers >1:152 (postdose positive ADAs)13710
Titers >1:152 (postdose positive nADAs)1167
SecondaryMedian Time to Seroconversion

Time to seroconversion (in days) was defined as the time to the observation of the first confirmed positive ADA response. Participants with confirmed positive ADA response at baseline (Week 0 predose) were excluded.

Time frame:
Up to Week 52
Reported as:
Median · days
Median Time to Seroconversion
daysPart 1 and Part 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Median Time to Seroconversion113.0 (52 to 372)113.0 (51 to 375)112.0 (54 to 373)

Adverse events

Collected over Up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: M9230/285 (0%)4/285 (1.4%)92/285 (32.3%)
Part 1: EU RPP0/285 (0%)7/285 (2.5%)104/285 (36.5%)
Part 2: M9230/271 (0%)10/271 (3.7%)96/271 (35.4%)
Part 2: Transition EU RPP0/132 (0%)10/132 (7.6%)47/132 (35.6%)
Part 2: Continuous EU RPP0/131 (0%)8/131 (6.1%)63/131 (48.1%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventPart 1: M923Part 1: EU RPPPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
CardiomyopathyCardiac disorders0/2850/2851/2710/1321/131
Left ventricular failureCardiac disorders0/2850/2850/2710/1321/131
Drug-induced liver injuryHepatobiliary disorders0/2850/2850/2710/1321/131
HypersensitivityImmune system disorders0/2850/2850/2710/1321/131
Hip fractureInjury, poisoning and procedural complications0/2850/2850/2710/1321/131
Meniscus injuryInjury, poisoning and procedural complications0/2850/2850/2711/1321/131
AppendicitisInfections and infestations0/2850/2851/2710/1321/131
Peritonsillar abscessInfections and infestations0/2850/2850/2710/1321/131
Ejection fraction decreasedInvestigations0/2850/2850/2710/1321/131
UreterolithiasisRenal and urinary disorders0/2850/2850/2710/1321/131
Most frequent other events
Most frequent other events
EventPart 1: M923Part 1: EU RPPPart 2: M923Part 2: Transition EU RPPPart 2: Continuous EU RPP
Injection site reactionGeneral disorders68/28579/28527/27115/13219/131
PsoriasisSkin and subcutaneous tissue disorders8/2858/28528/27114/13221/131
NasopharyngitisInfections and infestations19/28517/28540/27116/13220/131
Upper respiratory tract infectionInfections and infestations9/2856/28515/2716/13211/131
HeadacheNervous system disorders9/28510/2852/2717/1325/131

Baseline characteristics

Intent-to-Treat (ITT) Analysis Set: all consenting participants randomized to study treatment

Age, Continuous
Age, Continuous(years)Part 1 and Part 2: M923Part 1 and Part 2: EU RPPTotal
Mean44.6 ± 12.445.5 ± 12.945.0 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 and Part 2: M923Part 1 and Part 2: EU RPPTotal
Female95100195
Male191186377
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 and Part 2: M923Part 1 and Part 2: EU RPPTotal
American Indian or Alaska Native011
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American314
White281282563
More than one race000
Unknown or Not Reported011
Psoriasis Area and Severity Index (PASI) Score
Psoriasis Area and Severity Index (PASI) Score(units on a scale)Part 1 and Part 2: M923Part 1 and Part 2: EU RPPTotal
Mean21.24 ± 9.2720.16 ± 8.1620.70 ± 8.74
Number of Participants with the Indicated Static Physician's Global Assessment (sPGA) Score
Number of Participants with the Indicated Static Physician's Global Assessment (sPGA) Score(Participants)Part 1 and Part 2: M923Part 1 and Part 2: EU RPPTotal
Moderate170182352
Severe10391194
Very Severe121224
Clear000
Almost Clear000
Mild000
08

Study locations

90 sites
  • Wallace Medical Group, Inc.
    Beverly Hills, California 90211, United States
  • Encino Research Center
    Encino, California 91436, United States
  • eStudySite
    La Mesa, California 91942, United States
  • eStudySite
    Oceanside, California 92056, United States
  • eStudySite
    San Diego, California 92120, United States
  • Shahram Jacobs MD, INC
    Sherman Oaks, California 91403, United States
  • Horizons Clinical Research Center, LLC
    Denver, Colorado 80220, United States
  • Bioclinical Research Alliance; Inc
    Miami, Florida 33155, United States
  • Sanitas Reasearch, LLC
    Miami, Florida 33155, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • Radiant Research; Inc.
    Overland Park, Kansas 66210, United States
  • Tufts Medical Center; Inc.
    Boston, Massachusetts 02111, United States
  • Bay State Clinical Trials, Inc
    Watertown, Massachusetts 02472, United States
  • eStudySite
    Las Vegas, Nevada 89109, United States
  • Radiant Research; Inc.
    Cincinnati, Ohio 45249, United States
  • Radiant Research, Inc.
    Columbus, Ohio 43212, United States
  • Radiant Clinical Research
    Anderson, South Carolina 29621, United States
  • Palmetto Clinical Trial Services, LLC
    Fountain Inn, South Carolina 29644, United States
  • Radiant Research, Inc.
    Greer, South Carolina 29650, United States
  • Austin Institute for Clinical Research, LLC
    Pflugerville, Texas 78660, United States
  • Clinical Trials of Texas; Inc.
    San Antonio, Texas 78229, United States
  • National Clinical Research-Richmond, Inc
    Richmond, Virginia 23294, United States
  • Medical Centre Asklepii, OOD
    Dupnitsa, 2600, Bulgaria
  • DCC Sveti Georgi EOOD
    Haskovo, 6300, Bulgaria
  • UMHAT Dr.Georgi Stranski, EAD
    Pleven, 5800, Bulgaria
  • DCC Sv. Georgi, EOOD
    Plovdiv, 4000, Bulgaria
  • Department of Dermatology and Venereology, Faculty of Medicine, UMHAT Alexandrovska
    Sofia, 1431, Bulgaria
  • Mediprobe Research Inc
    London, Ontario N5X 2P1, Canada
  • SKDS Research Inc
    Newmarket, Ontario L3Y 5G8, Canada
  • North Bay Dermatology Centre
    North Bay, Ontario P1B 3Z7, Canada
  • Office of Dr. Michael Robern
    Ottawa, Ontario K2G 6E2, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario K2G 6E2, Canada
  • London Road Diagnostic Clinic and Medical Centre
    Sarnia, Ontario N7T 4X3, Canada
  • K Papp Clinical Research Inc
    Waterloo, Ontario N2J 1C4, Canada
  • Dr. David Gratton Dermatologue Inc.
    Montreal, Quebec H3H 1V4, Canada
  • Recherche GCP Research
    Montréal, Quebec H1M 1B1, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
    Ste-Foy, Quebec G1V 4X7, Canada
  • CCBR Czech Prague s.r.o
    Praha 3, Czech Republic 13000, Czechia
  • Dermatologie - MUDr. HELENA KORANDOVA s.r.o.
    Olomouc, Povel 779 00, Czechia
  • CCBR Czech Brno, s.r.o
    Brno, 60200, Czechia
  • CCBR Czech a.s
    Pardubice, 530 02, Czechia
  • Clintrial s.r.o
    Praha 10, 100 00, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 10, 100 34, Czechia
  • Krajska zdravotni a.s. - Masarykova nemocnice v Usti nad Labem Dermatovenerologicke oddeleni
    Usti nad Labem, 40113, Czechia
  • MUDr. Jaroslav Dragon - Kozni ordinace
    Ústí nad Labem, 400 10, Czechia
  • Parnu Hospital
    Pärnu, 80010, Estonia
  • Vahlberg & Pild OU
    Tallinn, 10134, Estonia
  • East Tallinn Central Hospital
    Tallinn, 11312, Estonia
  • North Estonia Medical Centre Foundation
    Tallinn, 13419, Estonia
  • Medicum AS
    Tallinn, 13619, Estonia
  • Kliiniliste Uuringute Keskus (Clinical Research Centre)
    Tartu, 50106, Estonia
  • Tartu University Hospital; Dermatology Clinic
    Tartu, 50417, Estonia
  • Universitaetsklinikum Schleswig Holstein
    Schleswig, Holstein 23538, Germany
  • Klinische Forschunq Schwerin GmbH
    Mecklenburg, Vorpommern 19055, Germany
  • Praxis fuer Dermatologie und Venerologie
    Dresden, 01097, Germany
  • Universitaetsklinikum Carl Gustav Carus TU Dresden
    Dresden, 01307, Germany
  • Klinikum der Johann Wolfgang Goethe-Universitaet
    Frankfurt am Main, 60590, Germany
  • Clinical Research Hamburg
    Hamburg, 22143, Germany
  • Riga 1 st Hospital
    Riga, 1001, Latvia
  • Derma Clinic Riga Ltd
    Riga, LV-1003, Latvia
  • Health Centre 4
    Riga, LV-1003, Latvia
  • J. Kisis Ltd
    Riga, LV-1003, Latvia
  • Health Centre 4
    Riga, LV-1013, Latvia
  • Ventspils Outpatient Clinic
    Ventspils, LV-3601, Latvia
  • Medica Pro Familia Sp. z o.o. S.K.A.
    Warsaw, Mazowieckie 01-868, Poland
  • Poradnia Kardiologiczna Jaroslaw Jurowiecki
    Gdansk, 80-286, Poland
  • Medica Pro Familia Sp. z o. o. S.K.A. Oddzial w Gdyni
    Gdynia, 81-338, Poland
  • NZOZ POLIMEDICA FILIA KIELCE (Niepubliczny Zaklad Opieki Zdrowotnej POLIMEDICA)
    Kielce, 25-364, Poland
  • Medica Pro Familia Sp. z o.o. SK.A.
    Krakow, 30-002, Poland
  • Grazyna Pulka Specjalistyczny Osrodek ALL-MED
    Krakow, 31-023, Poland
  • Centrum Terapii Wspolczesnej _J.M. Jasnorzewska Sp. Komandytowo-Akcyjna
    Lodz, 90-242, Poland
  • Centrum Medyczne Szpital Swietej Rodziny
    Lodz, 90-302, Poland
  • NZOZ ALL-MED Centrum Medyczne Specjalistyczne Gabinety Lekarskie
    Lodz, 94-048, Poland
  • KO-MED Centra Kliniczne Lublin II
    Lublin, 20-362, Poland
  • Medicome sp.zoo
    Oswiecim, 32-600, Poland
  • Centrum Badan Klinicznych S.C.
    Poznan, 60-773, Poland
  • Ai Centrum Medyczne
    Poznan, 61-113, Poland
  • KO-MED Centra Kliniczne Pulawy
    Pulawy, 24-100, Poland
  • Centrum Medyczne Medyk
    Rzeszow, 35-055, Poland
  • NZOZ Nasz Lekarz
    Torun, 87-100, Poland
  • MTZ Clinical Research Sp z o.o.
    Warsaw, 02-106, Poland
  • KO-MED Centra Kliniczne Zamosc
    Zamosc, 22-400, Poland
  • Nzoz Polimedica
    Zgierz, 95-100, Poland
  • Pedi-Derma s.r.o.
    Kosice, Kosicky Kraj 04011, Slovakia
  • Derma therapy spol. s.r.o.
    Bratislava, 851 01, Slovakia
  • Nemocnica Kosice-Saca, a.s., 1.sukromna nemocnica
    Kosice, 04015, Slovakia
  • Dema-beauty, s.r.o
    Nitra, 949 01, Slovakia
  • Sanare S.r.o
    Svidnik, 089 01, Slovakia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Apr 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 1 year 5 months after primary completion. A results delay was requested in Apr 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2015
First posted
Oct 21, 2015
Start
Sep 2015
Primary completionActual
Apr 4, 2017
CompletionActual
Apr 4, 2017
Results delay requested
Apr 2, 2018
Results first posted
Sep 12, 2018
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02581345
Responsible party
Sponsor
First posted
Oct 21, 2015
Start date
Sep 2015
Primary completion
Apr 4, 2017
Completion
Apr 4, 2017
Results posted
Sep 12, 2018
Last update
Oct 17, 2018

Study contacts

John Caminis, MD
study director · Shire

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion